keyword
https://read.qxmd.com/read/38315963/machine-learning-predicts-oxaliplatin-benefit-in-early-colon-cancer
#1
JOURNAL ARTICLE
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Corey Lipchik, Patrick G Gavin, Greg Yothers, Carmen J Allegra, Nicholas J Petrelli, Jennifer Marie Suga, Judith O Hopkins, Naoyuki G Saito, Terry Evans, Srinivas Jujjavarapu, Norman Wolmark, Peter C Lucas, Soonmyung Paik, Min Sun, Katherine L Pogue-Geile, Xinghua Lu
PURPOSE: A combination of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is the standard for adjuvant therapy of resected early-stage colon cancer (CC). Oxaliplatin leads to lasting and disabling neurotoxicity. Reserving the regimen for patients who benefit from oxaliplatin would maximize efficacy and minimize unnecessary adverse side effects. METHODS: We trained a new machine learning model, referred to as the colon oxaliplatin signature (COLOXIS) model, for predicting response to oxaliplatin-containing regimens...
February 5, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/33241186/validation-of-the-nsabp-nrg-oncology-8-gene-trastuzumab-benefit-signature-in-alliance-ncctg-n9831
#2
JOURNAL ARTICLE
Katherine L Pogue-Geile, Nan Song, Daniel J Serie, Ying Wang, Patrick G Gavin, Rim S Kim, Noriko Tanaka, Debora Fumagalli, Yusuke Taniyama, Zhuo Li, Priya Rastogi, Sandra M Swain, Eleftherios P Mamounas, Charles E Geyer, Norman Wolmark, Peter C Lucas, Soonmyung Paik, E Aubrey Thompson
Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer patients. NSABP investigators utilized gene expression profiles of N9831 patients (N = 892) to blindly assign patients to large-, moderate-, or no-trastuzumab benefit groups and then NCCTG investigators assessed the degree of trastuzumab benefit using Cox models adjusted for age, nodes, estrogen receptor/progesterone receptor status, tumor size, and grade...
October 2020: JNCI Cancer Spectrum
https://read.qxmd.com/read/33203645/neratinib-plus-cetuximab-in-quadruple-wt-kras-nras-braf-pik3ca-metastatic-colorectal-cancer-resistant-to-cetuximab-or-panitumumab-nsabp-fc-7-a-phase-ib-study
#3
JOURNAL ARTICLE
Samuel A Jacobs, James J Lee, Thomas J George, James L Wade, Philip J Stella, Ding Wang, Ashwin R Sama, Fanny Piette, Katherine L Pogue-Geile, Rim S Kim, Patrick G Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F Kiesel, Jan H Beumer, Norman Wolmark, Peter C Lucas, Carmen J Allegra, Ashok Srinivasan
PURPOSE: In metastatic colorectal cancer (mCRC), HER2 ( ERBB2 ) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combined with cetuximab, in patients with progressive disease (PD) on anti-EGFR treatment. PATIENTS AND METHODS: Twenty-one patients with quadruple-wild-type, refractory mCRC enrolled in this 3+3 phase Ib study. Standard dosage cetuximab was administered with neratinib at 120 mg, 160 mg, 200 mg, and 240 mg/day orally in 28-day cycles...
November 17, 2020: Clinical Cancer Research
https://read.qxmd.com/read/31969184/correction-to-nsabp-fb-7-a-phase-ii-randomized-neoadjuvant-trial-with-paclitaxel-trastuzumab-and-or-neratinib-followed-by-chemotherapy-and-postoperative-trastuzumab-in-her2-breast-cancer
#4
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M Orcutt, Marina E Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S Kim, Huichen Feng, Corey Lipchik, Peter C Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G Gavin, April D Balousek, Soonmyung Paik, Carmen J Allegra, Norman Wolmark, Katherine L Pogue-Geile
After the publication of this work [1] the authors have reported that in Table 3 The letter "T" in columns 5 and 7 should not be there.
January 22, 2020: Breast Cancer Research: BCR
https://read.qxmd.com/read/31796073/nsabp-fb-7-a-phase-ii-randomized-neoadjuvant-trial-with-paclitaxel-trastuzumab-and-or-neratinib-followed-by-chemotherapy-and-postoperative-trastuzumab-in-her2-breast-cancer
#5
JOURNAL ARTICLE
Samuel A Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M Orcutt, Marina E Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S Kim, Huichen Feng, Corey Lipchik, Peter C Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G Gavin, April D Balousek, Soonmyung Paik, Carmen J Allegra, Norman Wolmark, Katherine L Pogue-Geile
PURPOSE: The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+ ) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly paclitaxel followed by standard doxorubicin plus cyclophosphamide. The secondary aims include biomarker analyses. EXPERIMENTAL DESIGN: pCR was tested for association with treatment, gene expression, and a single nucleotide polymorphism (SNP) in the Fc fragment of the IgG receptor IIIa-158V/F (FCGR3A)...
December 3, 2019: Breast Cancer Research: BCR
https://read.qxmd.com/read/30888406/stromal-tumor-infiltrating-lymphocytes-in-nrg-oncology-nsabp-b-31-adjuvant-trial-for-early-stage-her2-positive-breast-cancer
#6
JOURNAL ARTICLE
Rim S Kim, Nan Song, Patrick G Gavin, Roberto Salgado, Hanna Bandos, Zuzana Kos, Giuseppe Floris, Gert Ggm Van den Eynden, Sunil Badve, Sandra Demaria, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Joseph P Costantino, Soonmyung Paik, Norman Wolmark, Charles E Geyer, Peter C Lucas, Katherine L Pogue-Geile
We retrospectively assessed association of stromal tumor-infiltrating lymphocytes (sTILs) with clinical outcomes and molecular variables reportedly predictive of trastuzumab-benefit in NSABP B-31 (N = 2,130). sTILs were assessed in 1,581 eligible B-31 cases utilizing all available H&E slides. Mean concordance between main reviewer and six other pathologists was 90.8% in 100 cases. Cox regressions were used to calculate hazard ratios (HRs). In chemotherapy and trastuzumab-added-to-chemotherapy arms, increases in sTILs, as a semi-continuous variable (combined arms HR = 0...
March 19, 2019: Journal of the National Cancer Institute
https://read.qxmd.com/read/29241223/tumour-sidedness-and-intrinsic-subtypes-in-patients-with-stage-ii-iii-colon-cancer-analysis-of-nsabp-c-07-nrg-oncology
#7
JOURNAL ARTICLE
S Rim Kim, Nan Song, Greg Yothers, Patrick G Gavin, Carmen J Allegra, Soonmyung Paik, Katherine L Pogue-Geile
BACKGROUND: We tested the association of colon tumour sidedness with prognosis and with molecular subtypes recently shown to be predictive of oxaliplatin benefit in stage III colon cancer. METHODS: NSABP/NRG C-07 trial (N=1603) was used to determine association of tumour sidedness with molecular subtypes and recurrence-free survival (RFS) and overall survival (OS). RESULTS: Sidedness was associated with molecular subtypes except stem-like/CMS4 subtype...
March 6, 2018: British Journal of Cancer
https://read.qxmd.com/read/29128898/21-gene-recurrence-score-for-prognosis-and-prediction-of-taxane-benefit-after-adjuvant-chemotherapy-plus-endocrine-therapy-results-from-nsabp-b-28-nrg-oncology
#8
RANDOMIZED CONTROLLED TRIAL
Eleftherios P Mamounas, Gong Tang, Soonmyung Paik, Frederick L Baehner, Qing Liu, Jong-Hyeon Jeong, S Rim Kim, Steven M Butler, Farid Jamshidian, Diana B Cherbavaz, Amy P Sing, Steven Shak, Thomas B Julian, Barry C Lembersky, D Lawrence Wickerham, Joseph P Costantino, Norman Wolmark
BACKGROUND: The 21-gene recurrence score (RS) predicts outcome and benefit from adjuvant chemotherapy benefit in breast cancer patients treated with adjuvant endocrine therapy. In the NSABP B-28 study, we evaluated the 21-gene RS for its prognostic impact and its ability to predict benefit from paclitaxel (P) in node-positive, estrogen receptor-positive (ER+) breast cancer patients treated with adjuvant chemotherapy plus tamoxifen. METHODS: The B-28 trial compared doxorubicin/cyclophosphamide (AC) with AC followed by P in 3060 patients...
February 2018: Breast Cancer Research and Treatment
https://read.qxmd.com/read/27812689/association-of-polymorphisms-in-fcgr2a-and-fcgr3a-with-degree-of-trastuzumab-benefit-in-the-adjuvant-treatment-of-erbb2-her2-positive-breast-cancer-analysis-of-the-nsabp-b-31-trial
#9
RANDOMIZED CONTROLLED TRIAL
Patrick G Gavin, Nan Song, S Rim Kim, Corey Lipchik, Nicole L Johnson, Hanna Bandos, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Jong-Hyeon Jeong, Joseph P Costantino, Norman Wolmark, Soonmyung Paik, Kay L Pogue-Geile
IMPORTANCE: Preclinical models and studies in the metastatic and neoadjuvant settings suggest that single nucleotide polymorphisms in FCGR3A and FCGR2A may be associated with differential response to trastuzumab in the treatment of ERBB2/HER2-positive breast cancer, by modulating antibody-dependent cell-mediated cytotoxic effects. OBJECTIVE: To evaluate the effect of FCGR2A and FCGR3A polymorphisms on trastuzumab efficacy in the adjuvant treatment of ERBB2/HER2-positive breast cancer...
March 1, 2017: JAMA Oncology
https://read.qxmd.com/read/27270348/clinical-outcome-from-oxaliplatin-treatment-in-stage-ii-iii-colon-cancer-according-to-intrinsic-subtypes-secondary-analysis-of-nsabp-c-07-nrg-oncology-randomized-clinical-trial
#10
RANDOMIZED CONTROLLED TRIAL
Nan Song, Katherine L Pogue-Geile, Patrick G Gavin, Greg Yothers, S Rim Kim, Nicole L Johnson, Corey Lipchik, Carmen J Allegra, Nicholas J Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
IMPORTANCE: Oxaliplatin added to fluorouracil plus leucovorin therapy for patients with colon cancer has been shown to provide significant but modest absolute benefit for disease-free survival. However, acute and chronic neurotoxic effects from this regimen underscore the need for markers that predict oxaliplatin benefit. OBJECTIVE: To test our hypothesis that molecular subtypes of colon cancer would be associated with differential prognosis and benefit from oxaliplatin added to fluorouracil plus leucovorin therapy...
September 1, 2016: JAMA Oncology
https://read.qxmd.com/read/25559813/intrinsic-subtypes-pik3ca-mutation-and-the-degree-of-benefit-from-adjuvant-trastuzumab-in-the-nsabp-b-31-trial
#11
JOURNAL ARTICLE
Katherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, Patrick G Gavin, Seong-Rim Kim, Nicole L Blackmon, Melanie Finnigan, Priya Rastogi, Louis Fehrenbacher, Eleftherios P Mamounas, Sandra M Swain, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
PURPOSE: Considerable molecular heterogeneity exists among human epidermal growth factor receptor 2 (HER2) -positive breast cancer regarding gene expression and mutation profiling. Evidence from preclinical, clinical neoadjuvant, and metastatic clinical trials suggested that PIK3CA mutational status and PAM50 intrinsic subtype of a tumor were markers of response to anti-HER2 therapies. We evaluated the predictive value of these two biomarkers in the adjuvant setting using archived tumor blocks from National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31...
April 20, 2015: Journal of Clinical Oncology
https://read.qxmd.com/read/24262440/predicting-degree-of-benefit-from-adjuvant-trastuzumab-in-nsabp-trial-b-31
#12
RANDOMIZED CONTROLLED TRIAL
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G Gavin, Debora Fumagalli, Lynn C Goldstein, Nour Sneige, Eike Burandt, Yusuke Taniyama, Olga L Bohn, Ahwon Lee, Seung-Il Kim, Megan L Reilly, Matthew Y Remillard, Nicole L Blackmon, Seong-Rim Kim, Zachary D Horne, Priya Rastogi, Louis Fehrenbacher, Edward H Romond, Sandra M Swain, Eleftherios P Mamounas, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. METHODS: Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay...
December 4, 2013: Journal of the National Cancer Institute
https://read.qxmd.com/read/23821759/defective-mismatch-repair-and-benefit-from-bevacizumab-for-colon-cancer-findings-from-nsabp-c-08
#13
RANDOMIZED CONTROLLED TRIAL
Kay Pogue-Geile, Greg Yothers, Yusuke Taniyama, Noriko Tanaka, Patrick Gavin, Linda Colangelo, Nicole Blackmon, Corey Lipchik, Seong Rim Kim, Saima Sharif, Carmen Allegra, Nicholas Petrelli, Michael J O'Connell, Norman Wolmark, Soonmyung Paik
National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the Kaplan-Meier method...
July 3, 2013: Journal of the National Cancer Institute
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.